Analyst Price Targets — DNTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 8:38 pm | Andy Chen | Wolfe Research | $98.00 | $87.48 | TheFly | Dianthus initiated with an Outperform at Wolfe Research |
| March 9, 2026 7:56 pm | Maury Raycroft | UBS | $98.00 | $79.23 | TheFly | Dianthus price target raised to $98 from $81 at Jefferies |
| March 9, 2026 7:51 pm | Maury Raycroft | Jefferies | $98.00 | $79.23 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $98 at Jefferies |
| March 9, 2026 4:36 pm | — | Robert W. Baird | $132.00 | $79.23 | TheFly | Dianthus price target raised to $132 from $67 at Baird |
| March 9, 2026 4:04 pm | Swayampakula Ramakanth | H.C. Wainwright | $130.00 | $79.23 | TheFly | Dianthus price target raised to $130 from $47 at H.C. Wainwright |
| March 9, 2026 2:15 pm | Trevor Allred | Oppenheimer | $145.00 | $80.88 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer |
| March 9, 2026 2:14 pm | Alex Thompson | Stifel Nicolaus | $120.00 | $80.60 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $120 at Stifel |
| March 9, 2026 11:31 am | — | Truist Financial | $110.00 | $79.23 | TheFly | Dianthus price target raised to $110 from $63 at Truist |
| February 11, 2026 1:02 pm | — | Wedbush | $55.00 | $49.70 | TheFly | Dianthus price target raised to $55 from $46 at Wedbush |
| January 29, 2026 1:06 pm | — | UBS | $125.00 | $53.23 | TheFly | Dianthus price target raised to $125 from $62 at Oppenheimer |
Latest News for DNTH
NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on May 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's…
8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr.
NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on April 1, 2026, to eight newly-hired, non-executive employees.
114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero.
JPMorgan Chase and Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 626.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,124 shares of the company's stock after purchasing an additional 58,746 shares during
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNTH.
U.S. House Trading
No House trades found for DNTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.